Bovine herpesvirus 4-based vector delivering a hybrid rat/human HER-2 oncoantigen efficiently protects mice from autochthonous Her-2⁺ mammary cancer

References

• Whenham N, D'Hondt V, Piccart MJ. HER2-positive breast cancer: from trastuzumab to innovatory anti-HER2 strategies. Clin Breast Cancer 2008; 8:38-49; PMID:18501058; http://dx.doi.org/10.3816/CBC.2008.n.002
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM. Amplification of c-erbB-2 and aggressive human breast tumors? Science 1988; 240:1795-8; PMID:3289120; http://dx.doi.org/10.1126/science.3289120
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707-12; PMID:2470152; http://dx.doi.org/10.1126/science.2470152
   PubMed Web of Science ®Google Scholar
• Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R, Reed R. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992; 10:1049-56; PMID:1351538
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2:127-37; PMID:11252954; http://dx.doi.org/10.1038/35052073
   PubMed Web of Science ®Google Scholar
• Atalay G, Cardoso F, Awada A, Piccart MJ. Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. Ann Oncol 2003; 14:1346-63; PMID:12954573; http://dx.doi.org/10.1093/annonc/mdg365
   PubMed Web of Science ®Google Scholar
• Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 2000; 19:6102-14; PMID:11156523; http://dx.doi.org/10.1038/sj.onc.1203973
   PubMed Web of Science ®Google Scholar
• Hudis CA. Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med 2007; 357:39-51; PMID:17611206; http://dx.doi.org/10.1056/NEJMra043186
   PubMed Web of Science ®Google Scholar
• McArthur HL, Hudis CA. Breast cancer chemotherapy. Cancer J 2007; 13:141-7; PMID:17620762; http://dx.doi.org/10.1097/PPO.0b013e318074dc6f
   PubMed Web of Science ®Google Scholar
• El-Sahwi K, Bellone S, Cocco E, Cargnelutti M, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli FA, Hui P et al. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. Br J Cancer 2010; 102:134-43; PMID:19920829; http://dx.doi.org/10.1038/sj.bjc.6605448
   PubMed Web of Science ®Google Scholar
• Higa GM, Abraham J. Lapatinib in the treatment of breast cancer. Expert Rev Anticancer Ther 2007; 7:1183-92; PMID:17892419; http://dx.doi.org/10.1586/14737140.7.9.1183
   PubMed Web of Science ®Google Scholar
• Quaglino E, Iezzi M, Mastini C, Amici A, Pericle F, Di Carlo E, Pupa SM, De Giovanni C, Spadaro M, Curcio C et al. Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. Cancer Res 2004; 64:2858-64; PMID:15087404; http://dx.doi.org/10.1158/0008-5472.CAN-03-2962
   PubMed Web of Science ®Google Scholar
• Quaglino E, Rolla S, Iezzi M, Spadaro M, Musiani P, De Giovanni C, Lollini PL, Lanzardo S, Forni G, Sanges R et al. Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. J Clin Invest 2004; 113:709-17; PMID:14991069; http://dx.doi.org/10.1172/JCI19850
   PubMed Web of Science ®Google Scholar
• Ambrosino E, Spadaro M, Iezzi M, Curcio C, Forni G, Musiani P, Wei WZ, Cavallo F. Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. Cancer Res 2006; 66:7734-40; PMID:16885376; http://dx.doi.org/10.1158/0008-5472.CAN-06-1432
   PubMed Web of Science ®Google Scholar
• Rolla S, Nicolo C, Malinarich S, Orsini M, Forni G, Cavallo F, Ria F. Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice. J Immunol 2006; 177:7626-33; PMID:17114432; http://dx.doi.org/10.4049/jimmunol.177.11.7626
   PubMed Web of Science ®Google Scholar
• Holmgren L, Ambrosino E, Birot O, Tullus C, Veitonmaki N, Levchenko T, Carlson LM, Musiani P, Iezzi M, Curcio C et al. A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth. Proc Natl Acad Sci U S A 2006; 103:9208-13; PMID:16754857; http://dx.doi.org/10.1073/pnas.0603110103
   PubMed Web of Science ®Google Scholar
• Pannellini T, Spadaro M, Di Carlo E, Ambrosino E, Iezzi M, Amici A, Lollini PL, Forni G, Cavallo F, Musiani P. Timely DNA vaccine combined with systemic IL-12 prevents parotid carcinomas before a dominant-negative p53 makes their growth independent of HER-2/neu expression. J Immunol 2006; 176:7695-703; PMID:16751417; http://dx.doi.org/10.4049/jimmunol.176.12.7695
   PubMed Web of Science ®Google Scholar
• Rizzuto GA, Merghoub T, Hirschhorn-Cymerman D, Liu C, Lesokhin AM, Sahawneh D, Zhong H, Panageas KS, Perales MA, Altan-Bonnet G et al. Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. J Exp Med 2009; 206:849-66; PMID:19332877; http://dx.doi.org/10.1084/jem.20081382
   PubMed Web of Science ®Google Scholar
• Engelhorn ME, Guevara-Patino JA, Noffz G, Hooper AT, Lou O, Gold JS, Kappel BJ, Houghton AN. Autoimmunity and tumor immunity induced by immune responses to mutations in self. Nat Med 2006; 12:198-206; PMID:16444264; http://dx.doi.org/10.1038/nm1363
   PubMed Web of Science ®Google Scholar
• Luo W, Hsu JC, Kieber-Emmons T, Wang X, Ferrone S. Human tumor associated antigen mimicry by xenoantigens, anti-idiotypic antibodies and peptide mimics: implications for immunotherapy of malignant diseases. Cancer Chemother Biol Response Modif 2005; 22:769-87; PMID:16110640; http://dx.doi.org/10.1016/S0921-4410(04)22036-1
   PubMedGoogle Scholar
• Quaglino E, Mastini C, Amici A, Marchini C, Iezzi M, Lanzardo S, De Giovanni C, Montani M, Lollini PL, Masucci G et al. A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins. Cancer Res 2010; 70:2604-12; PMID:20332241; http://dx.doi.org/10.1158/0008-5472.CAN-09-2548
   PubMed Web of Science ®Google Scholar
• Bolli E, Quaglino E, Arigoni M, Lollini PL, Calogero R, Forni G, Cavallo F. Oncoantigens for an immune prevention of cancer. Am J Cancer Res 2011; 1:255-64; PMID:21969087
   PubMed Web of Science ®Google Scholar
• Jacob JB, Quaglino E, Radkevich-Brown O, Jones RF, Piechocki MP, Reyes JD, Weise A, Amici A, Wei WZ. Combining human and rat sequences in her-2 DNA vaccines blunts immune tolerance and drives antitumor immunity. Cancer Res 2010; 70:119-28; PMID:20048073; http://dx.doi.org/10.1158/0008-5472.CAN-09-2554
   PubMed Web of Science ®Google Scholar
• Donofrio G, Cavirani S, Simone T, van Santen VL. Potential of bovine herpesvirus 4 as a gene delivery vector. J Virol Methods 2002; 101:49-61; PMID:11849683; http://dx.doi.org/10.1016/S0166-0934(01)00419-0
   PubMed Web of Science ®Google Scholar
• Donofrio G, Sartori C, Ravanetti L, Cavirani S, Gillet L, Vanderplasschen A, Taddei S, Flammini CF. Establishment of a bovine herpesvirus 4 based vector expressing a secreted form of the bovine viral diarrhoea virus structural glycoprotein E2 for immunization purposes. BMC Biotechnol 2007; 7:68; PMID:17945009; http://dx.doi.org/10.1186/1472-6750-7-68
   PubMed Web of Science ®Google Scholar
• Donofrio G, Sartori C, Franceschi V, Capocefalo A, Cavirani S, Taddei S, Flammini CF. Double immunization strategy with a BoHV-4-vectorialized secreted chimeric peptide BVDV-E2/BoHV-1-gD. Vaccine 2008; 26:6031-42; PMID:18812200; http://dx.doi.org/10.1016/j.vaccine.2008.09.023
   PubMed Web of Science ®Google Scholar
• Donofrio G, Franceschi V, Capocefalo A, Taddei S, Sartori C, Bonomini S, Cavirani S, Cabassi CS, Flammini CF. Cellular targeting of engineered heterologous antigens is a determinant factor for bovine herpesvirus 4-based vaccine vector development. Clin Vaccine Immunol 2009; 16:1675-86; PMID:19793901; http://dx.doi.org/10.1128/CVI.00224-09
   PubMed Web of Science ®Google Scholar
• Franceschi V, Capocefalo A, Calvo-Pinilla E, Redaelli M, Mucignat-Caretta C, Mertens P, Ortego J, Donofrio G. Immunization of knock-out α/β interferon receptor mice against lethal bluetongue infection with a BoHV-4-based vector expressing BTV-8 VP2 antigen. Vaccine 2011; 29:3074-82; PMID:21320537; http://dx.doi.org/10.1016/j.vaccine.2011.01.075
   PubMed Web of Science ®Google Scholar
• Redaelli M, Franceschi V, Capocefalo A, D'Avella D, Denaro L, Cavirani S, Mucignat-Caretta C, Donofrio G. Herpes simplex virus type 1 thymidine kinase-armed bovine herpesvirus type 4-based vector displays enhanced oncolytic properties in immunocompetent orthotopic syngenic mouse and rat glioma models. Neuro-oncology 2012; 14:288-301; PMID:22228853; http://dx.doi.org/10.1093/neuonc/nor219
   PubMed Web of Science ®Google Scholar
• Donofrio G, Franceschi V, Lovero A, Capocefalo A, Camero M, Losurdo M, Cavirani S, Marinaro M, Grandolfo E, Buonavoglia C et al. Clinical protection of goats against CpHV-1 induced genital disease with a BoHV-4-based vector expressing CpHV-1 gD. PloS one 2013; 8:e52758; PMID:23300989; http://dx.doi.org/10.1371/journal.pone.0052758
   PubMedGoogle Scholar
• Donofrio G, Martignani E, Poli E, Lange C, Martini FM, Cavirani S, Cabassi CS, Taddei S, Flammini CF. Bovine herpesvirus 4 based vector interaction with liver cells in vitro and in vivo. J Virol Methods 2006; 136:126-36; PMID:16712963; http://dx.doi.org/10.1016/j.jviromet.2006.04.008
   PubMed Web of Science ®Google Scholar
• Donofrio G, Taddei S, Franceschi V, Capocefalo A, Cavirani S, Martinelli N, Ottonello S, Ferrari M. Swine adipose stromal cells loaded with recombinant bovine herpesvirus 4 virions expressing a foreign antigen induce potent humoral immune responses in pigs. Vaccine 2011; 29:867-72; PMID:21115049; http://dx.doi.org/10.1016/j.vaccine.2010.11.048
   PubMed Web of Science ®Google Scholar
• Franceschi V, Stellari FF, Mangia C, Jacca S, Lavrentiadou S, Cavirani S, Heikenwalder M, Donofrio G. In vivo image analysis of BoHV-4-based vector in mice. PloS one 2014; 9:e95779; PMID:24752229; http://dx.doi.org/10.1371/journal.pone.0095779
   PubMedGoogle Scholar
• Osorio FA, Reed DE. Experimental inoculation of cattle with bovine herpesvirus-4: evidence for a lymphoid-associated persistent infection. Am J Vet Res 1983; 44:975-80; PMID:6307096
   PubMed Web of Science ®Google Scholar
• Capocefalo A, Franceschi V, Mertens PP, Castillo-Olivares J, Cavirani S, Di Lonardo E, Leni Z, Donofrio G. Expression and secretion of Bluetongue virus serotype 8 (BTV-8)VP2 outer capsid protein by mammalian cells. J Virol Methods 2010; 169:420-4; PMID:20705105; http://dx.doi.org/10.1016/j.jviromet.2010.08.002
   PubMed Web of Science ®Google Scholar
• Franceschi V, Parker S, Jacca S, Crump RW, Doronin K, Hembrador E, Pompilio D, Tebaldi G, Estep RD, Wong SW et al. BoHV-4-Based Vector Single Heterologous Antigen Delivery Protects STAT1(-/-) Mice from Monkeypoxvirus Lethal Challenge. PLoS Negl Trop Dis 2015; 9:e0003850; PMID:26086739; http://dx.doi.org/10.1371/journal.pntd.0003850
   PubMed Web of Science ®Google Scholar
• Quaglino E, Mastini C, Forni G, Cavallo F. ErbB2 transgenic mice: a tool for investigation of the immune prevention and treatment of mammary carcinomas. Curr Protoc Immunol 2008; Chapter 20:Unit 200 9 1- 9-10; PMID:18729063; http://dx.doi.org/10.1002/0471142735.im2009s82
   PubMedGoogle Scholar
• Franceschi V, Capocefalo A, Cavirani S, Donofrio G. Bovine herpesvirus 4 glycoprotein B is indispensable for lytic replication and irreplaceable by VSVg. BMC Vet Res 2013; 9:6; PMID:23302472; http://dx.doi.org/10.1186/1746-6148-9-6
   PubMed Web of Science ®Google Scholar
• Capocefalo A, Mangia C, Franceschi V, Jacca S, van Santen VL, Donofrio G. Efficient heterologous antigen gene delivery and expression by a replication-attenuated BoHV-4-based vaccine vector. Vaccine 2013; 31:3906-14; PMID:23830977; http://dx.doi.org/10.1016/j.vaccine.2013.06.052
   PubMed Web of Science ®Google Scholar
• Warming S, Costantino N, Court DL, Jenkins NA, Copeland NG. Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res 2005; 33:e36; PMID:15731329; http://dx.doi.org/10.1093/nar/gni035
   PubMed Web of Science ®Google Scholar
• Rovero S, Amici A, Di Carlo E, Bei R, Nanni P, Quaglino E, Porcedda P, Boggio K, Smorlesi A, Lollini PL et al. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 2000; 165:5133-42; PMID:11046045; http://dx.doi.org/10.4049/jimmunol.165.9.5133
   PubMed Web of Science ®Google Scholar
• Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, Forni G, Eils R, Fehm T, Riethmüller G et al. Systemic spread is an early step in breast cancer. Cancer Cell 2008; 13:58-68; PMID:18167340; http://dx.doi.org/10.1016/j.ccr.2007.12.003
   PubMed Web of Science ®Google Scholar
• Melani C, Chiodoni C, Forni G, Colombo MP. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 2003; 102:2138-45; PMID:12750171; http://dx.doi.org/10.1182/blood-2003-01-0190
   PubMed Web of Science ®Google Scholar
• Matic S, Quaglino E, Arata L, Riccardo F, Pegoraro M, Vallino M, Cavallo F, Noris E. The rat ErbB2 tyrosine kinase receptor produced in plants is immunogenic in mice and confers protective immunity against ErbB2 mammary cancer. Plant biotechnology journal 2015; PMID:25865255
   PubMed Web of Science ®Google Scholar
• Gershoni JM, Roitburd-Berman A, Siman-Tov DD, Tarnovitski Freund N, Weiss Y. Epitope mapping: the first step in developing epitope-based vaccines. BioDrugs 2007; 21:145-56; PMID:17516710; http://dx.doi.org/10.2165/00063030-200721030-00002
   PubMed Web of Science ®Google Scholar
• Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW, Jr., Leahy DJ. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003; 421:756-60; PMID:12610629; http://dx.doi.org/10.1038/nature01392
   PubMed Web of Science ®Google Scholar
• Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004; 5:317-28; PMID:15093539; http://dx.doi.org/10.1016/S1535-6108(04)00083-2
   PubMed Web of Science ®Google Scholar
• Porzia A, Lanzardo S, Citti A, Cavallo F, Forni G, Santoni A, Galandrini R, Paolini R. Attenuation of PI3K/Akt-mediated tumorigenic signals through PTEN activation by DNA vaccine-induced anti-ErbB2 antibodies. J Immunol 2010; 184:4170-7; PMID:20220087; http://dx.doi.org/10.4049/jimmunol.0903375
   PubMed Web of Science ®Google Scholar
• Park JM, Terabe M, Sakai Y, Munasinghe J, Forni G, Morris JC, Berzofsky JA. Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas. J Immunol 2005; 174:4228-36; PMID:15778385; http://dx.doi.org/10.4049/jimmunol.174.7.4228
   PubMed Web of Science ®Google Scholar
• Tegerstedt K, Lindencrona JA, Curcio C, Andreasson K, Tullus C, Forni G, Dalianis T, Kiessling R, Ramqvist T. A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors. Cancer Res 2005; 65:5953-7; PMID:15994974; http://dx.doi.org/10.1158/0008-5472.CAN-05-0335
   PubMed Web of Science ®Google Scholar
• Gallo P, Dharmapuri S, Nuzzo M, Maldini D, Cipriani B, Forni G, Monaci P. Adenovirus vaccination against neu oncogene exerts long-term protection from tumorigenesis in BALB/neuT transgenic mice. Int J Cancer 2007; 120:574-84; PMID:17096348; http://dx.doi.org/10.1002/ijc.22274
   PubMed Web of Science ®Google Scholar
• Dols A, Meijer SL, Smith JW, 2nd, Fox BA, Urba WJ. Allogeneic breast cancer cell vaccines. Clin Breast Cancer 2003; 3 Suppl 4:S173-80; PMID:12620156; http://dx.doi.org/10.3816/CBC.2003.s.008
   PubMedGoogle Scholar
• Dols A, Smith JW, 2nd, Meijer SL, Fox BA, Hu HM, Walker E, Rosenheim S, Moudgil T, Doran T, Wood W et al. Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological results. Hum Gene Ther 2003; 14:1117-23; PMID:12885350; http://dx.doi.org/10.1089/104303403322124828
   PubMed Web of Science ®Google Scholar
• Dols A, Meijer SL, Hu HM, Goodell V, Disis ML, Von Mensdorff-Pouilly S, Verheijen R, Alvord WG, Smith JW 2nd, Urba WJ et al. Identification of tumor-specific antibodies in patients with breast cancer vaccinated with gene-modified allogeneic tumor cells. J Immunother 2003; 26:163-70; PMID:12616108; http://dx.doi.org/10.1097/00002371-200303000-00009
   PubMed Web of Science ®Google Scholar
• Park JW, Melisko ME, Esserman LJ, Jones LA, Wollan JB, Sims R. Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer. J Clin Oncol 2007; 25:3680-7; PMID:17704416; http://dx.doi.org/10.1200/JCO.2006.10.5718
   PubMed Web of Science ®Google Scholar
• Occhipinti S, Sponton L, Rolla S, Caorsi C, Novarino A, Donadio M, Bustreo S, Satolli MA, Pecchioni C, Marchini C et al. Chimeric rat/human HER2 efficiently circumvents HER2 tolerance in cancer patients. Clin Cancer Res 2014; 20:2910-21; PMID:24668647; http://dx.doi.org/10.1158/1078-0432.CCR-13-2663
   PubMed Web of Science ®Google Scholar
• Kitano S, Kageyama S, Nagata Y, Miyahara Y, Hiasa A, Naota H, Okumura S, Imai H, Shiraishi T, Masuya M et al. HER2-specific T-cell immune responses in patients vaccinated with truncated HER2 protein complexed with nanogels of cholesteryl pullulan. Clin Cancer Res 2006; 12:7397-405; PMID:17189412; http://dx.doi.org/10.1158/1078-0432.CCR-06-1546
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Holmes JP, Ponniah S, Peoples GE. The E75 HER2/neu peptide vaccine. Cancer Immunol Immunother 2008; 57:1511-21; PMID:18536917; http://dx.doi.org/10.1007/s00262-008-0540-3
   PubMed Web of Science ®Google Scholar
• Aurisicchio L, Peruzzi D, Conforti A, Dharmapuri S, Biondo A, Giampaoli S, Fridman A, Bagchi A, Winkelmann CT, Gibson R et al. Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9. Clin Cancer Res 2009; 15:1575-84; PMID:19240169; http://dx.doi.org/10.1158/1078-0432.CCR-08-2628
   PubMed Web of Science ®Google Scholar
• Andreasson K, Tegerstedt K, Eriksson M, Curcio C, Cavallo F, Forni G, Dalianis T, Ramqvist T. Murine pneumotropic virus chimeric Her2/neu virus-like particles as prophylactic and therapeutic vaccines against Her2/neu expressing tumors. Int J Cancer 2009; 124:150-6; PMID:18839427; http://dx.doi.org/10.1002/ijc.23920
   PubMed Web of Science ®Google Scholar
• Seavey MM, Pan ZK, Maciag PC, Wallecha A, Rivera S, Paterson Y, Shahabi V. A novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumors. Clin Cancer Res 2009; 15:924-32; PMID:19188163; http://dx.doi.org/10.1158/1078-0432.CCR-08-2283
   PubMed Web of Science ®Google Scholar
• Masuelli L, Marzocchella L, Focaccetti C, Lista F, Nardi A, Scardino A, Mattei M, Turriziani M, Modesti M, Forni G et al. Local delivery of recombinant vaccinia virus encoding for neu counteracts growth of mammary tumors more efficiently than systemic delivery in neu transgenic mice. Cancer Immunol Immunother 2010; 59:1247-58; PMID:20364378; http://dx.doi.org/10.1007/s00262-010-0850-0
   PubMed Web of Science ®Google Scholar
• Masuelli L, Fantini M, Benvenuto M, Sacchetti P, Giganti MG, Tresoldi I, Lido P, Lista F, Cavallo F, Nanni P et al. Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cells. J Transl Med 2014; 12:122; PMID:24886178; http://dx.doi.org/10.1186/1479-5876-12-122
   PubMed Web of Science ®Google Scholar
• Park JM, Terabe M, Steel JC, Forni G, Sakai Y, Morris JC, Berzofsky JA. Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccine. Cancer Res 2008; 68:1979-87; PMID:18339880; http://dx.doi.org/10.1158/0008-5472.CAN-07-5688
   PubMed Web of Science ®Google Scholar
• Donofrio G, Cavaggioni A, Bondi M, Cavirani S, Flammini CF, Mucignat-Caretta C. Outcome of bovine herpesvirus 4 infection following direct viral injection in the lateral ventricle of the mouse brain. Microbes Infection 2006; 8:898-904; PMID:16503181; http://dx.doi.org/10.1016/j.micinf.2005.10.016
   PubMed Web of Science ®Google Scholar
• Jacob J, Radkevich O, Forni G, Zielinski J, Shim D, Jones RF, Wei WZ. Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice. Cell Immunol 2006; 240:96-106; PMID:16930573; http://dx.doi.org/10.1016/j.cellimm.2006.07.002
   PubMed Web of Science ®Google Scholar
• Marchini C, Kalogris C, Garulli C, Pietrella L, Gabrielli F, Curcio C, Quaglino E, Cavallo F, Amici A. Tailoring DNA Vaccines: Designing Strategies Against HER2-Positive Cancers. Front Oncol 2013; 3:122; PMID:23675574; http://dx.doi.org/10.3389/fonc.2013.00122
   PubMedGoogle Scholar
• Boggio K, Nicoletti G, Di Carlo E, Cavallo F, Landuzzi L, Melani C, Giovarelli M, Rossi I, Nanni P, De Giovanni C et al. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med 1998; 188:589-96; PMID:9687535; http://dx.doi.org/10.1084/jem.188.3.589
   PubMed Web of Science ®Google Scholar
• Barutello G, Curcio C, Spadaro M, Arigoni M, Trovato R, Bolli E, Zheng Y, Ria F, Quaglino E, Iezzi M et al. Antitumor immunization of mothers delays tumor development in cancer-prone offspring. Oncoimmunology 2015; 4:e1005500; PMID:26155401; http://dx.doi.org/10.1080/2162402X.2015.1005500
   PubMedGoogle Scholar